JPRN-jRCT1031190032招募中3 期
JCOG1701: Randomized phase III study comparing cessation or continuation of PD-1 Pathway Blockade for patients with advanced non-small-cell lung cancer - SAVE study
OHE Yuichiro0 个研究点目标入组 172 人开始时间: 2019年5月28日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 172
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Histologically confirmed non-small cell lung cancer (adenocarcinoma, squamous carcinoma, LCNEC, carcinoid tumor, large-cell carcinoma, adenosquamous carcinoma, sarcomatoid cancer, unclassifiable cancer, and salivary gland tumor) or cytologically (including biopsy) confirmed non-small cell lung cancer (adenocarcinoma, squamous carcinoma, adenocarcinoma-suggested, squamous-suggested, LCNEC-suggested, and NOS).
- •(2) Treated with anti-PD-1 or anti-PD-L1 inhibitor for 52 weeks or more and not over 62 weeks.
- •(3) Remarkable response of anti-PD-1 or anti-PD-L1 inhibitor measured by comparing CT imaging of before the treatment and that of taken within 4 weeks before the enrollment.
- •(4) 20 years of age or older.
- •(5) ECOG performance status, 0 or 1.
- •(6) None of the treatment below should be done within 8 weeks before the enrollment.
- •(i) radiotherapy (for metastatic sites).
- •(ii) chest drainage for more than 24 hours.
- •(iii) pleurodesis.
- •(iv) surgery with general anesthesia.
- •(7) No adverse reactions with grade 3 or more, related to anti-PD-1 or PD-L1 inhibitors.
- •(8) No pneumonitis with grade 3 or more, even not related to the pretreated anti-PD-1 or PD-L1 inhibitors.
- •(9) No active, chronic or recurrent autoimmune disease.
- •(10) No symptomatic brain metastasis, meningeal carcinoma, and spinal metastasis which needs radiotherapy or surgery.
- •(11) No superior vena cava syndrome, pericardial water retention, pleural effusion, and ascites with grade 3 or more.
- •(12) Adequate function of major organs.
- •(13) Written informed consent.
排除标准
- •(1) Synchronous or metachronous (within 2 years) malignancies. (2) Infectious disease requiring systemic treatment. (3) Pyrexia of 38 or higher degrees centigrade. (4) Female during pregnancy, within 28 days of postparturition, or during lactation and male expecting partner's pregnancy. (5) Severe psychological disorders. (6) Patients requiring systemic steroids medication or immunosuppressants for non-autoimmune disease.
- •(7) Poorly controlled diabetes mellitus. (8) Poorly controlled hypertension. (9) History of unstable angina pectoris with new onset or exacerbation within recent 3 weeks or myocardial infarction within 6 months before registration.
- •(10) Positive HBs antigen.
研究者
相似试验
招募中
3 期
JCOG2103: Randomized phase III study comparing systemic therapy and debulking surgery consisting of primary tumor resection with systemic therapy alone for clinical stage IVA (cT1-2bN0-1M1a) non-small cell lung cancer with radiologically undetermined pleural disseminatioJPRN-jRCTs031220666WATANABE Shun-ichi170
进行中（未招募）
3 期
JCOG1703: A multicenter randomized phase III study for newly-diagnosed maximally resected glioblastoma comparing Carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy aloneglioblastomaJPRN-jRCT1031190035KUMABE Toshihiro250
招募中
3 期
JCOG2107E: A randomized phase III trial comparing etoposide plus carboplatin combination therapy with/without durvalumab (MEDI4736) for advanced neuroendocrine carcinoma of the digestive systemneuroendocrine carcinoma of the digestive systemJPRN-jRCT2031230456Morizane Chigusa74
进行中（未招募）
3 期
JCOG1109: A randomized controlled phase III comparing CF versus DCF versus CF-RT as neoadjuvant treatment for locally advanced esophageal cancerclinical stage IB/II/III thoracic esophageal cancerJPRN-jRCTs031180202Kato Ken600
进行中（未招募）
3 期
JCOG1314: A randomized controlled phase III study comparing docetaxel, CDDP and 5-FU with CDDP and 5-FU in patients with metastatic or recurrent esophageal canceresophageal cancerJPRN-jRCTs031180143TSUBOSA Yasuhiro240